Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more
Caris Life Sciences, Inc. Common Stock (CAI) - Net Assets
Latest net assets as of December 2025: $577.31 Million USD
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has net assets worth $577.31 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.13 Billion) and total liabilities ($548.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $577.31 Million |
| % of Total Assets | 51.29% |
| Annual Growth Rate | 17.98% |
| 5-Year Change | -17.79% |
| 10-Year Change | 25.16% |
| Growth Volatility | 120.82 |
Caris Life Sciences, Inc. Common Stock - Net Assets Trend (2003–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Caris Life Sciences, Inc. Common Stock (2003–2025)
The table below shows the annual net assets of Caris Life Sciences, Inc. Common Stock from 2003 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $577.31 Million | +123.10% |
| 2024-12-31 | $-2.50 Billion | -16.50% |
| 2023-12-31 | $-2.14 Billion | -26.02% |
| 2022-12-31 | $-1.70 Billion | -342.38% |
| 2020-12-31 | $702.24 Million | +1.30% |
| 2019-12-31 | $693.24 Million | -1.13% |
| 2018-12-31 | $701.13 Million | +24.35% |
| 2017-12-31 | $563.85 Million | +23.24% |
| 2016-12-31 | $457.50 Million | -0.81% |
| 2015-12-31 | $461.26 Million | +4.14% |
| 2014-12-31 | $442.90 Million | +6.69% |
| 2013-12-31 | $415.13 Million | +19.69% |
| 2012-12-31 | $346.85 Million | +39.44% |
| 2011-12-31 | $248.74 Million | +25.83% |
| 2010-12-31 | $197.67 Million | +53.12% |
| 2009-12-31 | $129.10 Million | +13.45% |
| 2008-12-31 | $113.79 Million | -13.24% |
| 2007-12-31 | $131.15 Million | +372.52% |
| 2006-12-31 | $27.75 Million | -15.88% |
| 2005-12-31 | $32.99 Million | +38.51% |
| 2004-12-31 | $23.82 Million | +56.95% |
| 2003-12-31 | $15.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Caris Life Sciences, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 254873600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $283.00K | 0.05% |
| Other Comprehensive Income | $936.00K | 0.16% |
| Other Components | $3.12 Billion | 541.28% |
| Total Equity | $577.31 Million | 100.00% |
Caris Life Sciences, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aerospace CH UAV Co Ltd
SHE:002389
|
$1.81 Billion |
|
Elekta AB (publ)
PINK:EKTAF
|
$1.81 Billion |
|
Koza Altin Islemeleri A S
PINK:KOZAY
|
$1.82 Billion |
|
Schaeffler India Limited
NSE:SCHAEFFLER
|
$1.82 Billion |
|
National Storage REIT
PINK:NTSGF
|
$1.81 Billion |
|
Shanghai V-Test Semiconductor Tech Co. Ltd. A
SHG:688372
|
$1.81 Billion |
|
Vera Therapeutics Inc
NASDAQ:VERA
|
$1.81 Billion |
|
Hammerson plc
PINK:HMSNF
|
$1.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Caris Life Sciences, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,498,838,000 to 577,307,000, a change of 3,076,145,000.
- Net loss of 537,957,000 reduced equity.
- Share repurchases of 113,000 reduced equity.
- New share issuances of 649,697,000 increased equity.
- Other comprehensive income increased equity by 726,000.
- Other factors increased equity by 2,963,792,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-537.96 Million | -93.18% |
| Share Repurchases | $113.00K | -0.02% |
| Share Issuances | $649.70 Million | +112.54% |
| Other Comprehensive Income | $726.00K | +0.13% |
| Other Changes | $2.96 Billion | +513.38% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Caris Life Sciences, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 53.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 25.86x to 53.70x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $0.72 | $18.54 | x |
| 2004-12-31 | $1.13 | $18.54 | x |
| 2005-12-31 | $1.56 | $18.54 | x |
| 2006-12-31 | $1.31 | $18.54 | x |
| 2007-12-31 | $7.86 | $18.54 | x |
| 2008-12-31 | $6.54 | $18.54 | x |
| 2009-12-31 | $7.21 | $18.54 | x |
| 2010-12-31 | $9.87 | $18.54 | x |
| 2011-12-31 | $11.68 | $18.54 | x |
| 2012-12-31 | $17.39 | $18.54 | x |
| 2013-12-31 | $18.28 | $18.54 | x |
| 2014-12-31 | $20.90 | $18.54 | x |
| 2015-12-31 | $21.93 | $18.54 | x |
| 2016-12-31 | $23.59 | $18.54 | x |
| 2017-12-31 | $28.76 | $18.54 | x |
| 2018-12-31 | $35.38 | $18.54 | x |
| 2019-12-31 | $38.49 | $18.54 | x |
| 2020-12-31 | $39.12 | $18.54 | x |
| 2022-12-31 | $-6.68 | $18.54 | x |
| 2023-12-31 | $-8.42 | $18.54 | x |
| 2024-12-31 | $-9.81 | $18.54 | x |
| 2025-12-31 | $0.35 | $18.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Caris Life Sciences, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -93.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -66.25%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.95x
- Recent ROE (-93.18%) is below the historical average (4.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -17.45% | -5.51% | 0.25x | 12.72x | $-4.17 Million |
| 2004 | 38.74% | 13.84% | 0.37x | 7.64x | $6.85 Million |
| 2005 | 30.27% | 16.22% | 0.34x | 5.48x | $6.69 Million |
| 2006 | 18.85% | 28.12% | 0.07x | 10.20x | $2.46 Million |
| 2007 | 14.67% | 29.65% | 0.18x | 2.74x | $6.12 Million |
| 2008 | -23.69% | -32.42% | 0.20x | 3.63x | $-38.33 Million |
| 2009 | 10.50% | 20.77% | 0.17x | 2.90x | $646.20K |
| 2010 | 15.80% | 36.44% | 0.13x | 3.42x | $10.42 Million |
| 2011 | 21.82% | 39.93% | 0.13x | 4.14x | $27.19 Million |
| 2012 | 18.30% | 36.49% | 0.13x | 4.00x | $28.78 Million |
| 2013 | 15.42% | 30.10% | 0.13x | 4.04x | $22.47 Million |
| 2014 | 13.63% | 26.48% | 0.13x | 4.06x | $16.06 Million |
| 2015 | 5.83% | 10.75% | 0.13x | 4.32x | $-19.20 Million |
| 2016 | 1.31% | 2.04% | 0.14x | 4.49x | $-39.75 Million |
| 2017 | 12.78% | 20.68% | 0.14x | 4.31x | $15.68 Million |
| 2018 | 11.21% | 18.19% | 0.14x | 4.30x | $8.48 Million |
| 2019 | 4.47% | 7.44% | 0.14x | 4.19x | $-38.31 Million |
| 2020 | 3.95% | 9.43% | 0.11x | 3.72x | $-42.49 Million |
| 2022 | 0.00% | -124.12% | 0.36x | 0.00x | $-150.62 Million |
| 2023 | 0.00% | -111.53% | 0.74x | 0.00x | $-126.92 Million |
| 2024 | 0.00% | -68.38% | 1.20x | 0.00x | $-32.01 Million |
| 2025 | -93.18% | -66.25% | 0.72x | 1.95x | $-595.69 Million |
Industry Comparison
This section compares Caris Life Sciences, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Caris Life Sciences, Inc. Common Stock (CAI) | $577.31 Million | -17.45% | 0.95x | $1.81 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |